Who Owns Xilio Therapeutics Stock?
NASDAQ: XLOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 50.16%
- Held by insiders
- 25.98%
- Institutional holders
- 32
- Institutions 50.2%
- Insiders 26.0%
- Public and other 23.9%
Who owns Xilio Therapeutics stock?
Institutional investors own about 50.2% of Xilio Therapeutics's shares, spread across 32 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 25.98% of XLO.
The largest institutional holders are Bain Capital Life Sciences Investors, LLC (10.09%), Gilead Sciences Inc (9.88%) and Orbimed Advisors LLC. (9.00%). Together, the top 10 institutions control 48.1% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their XLO positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of XLO
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664.02K | 10.09% | 0.0% |
| Gilead Sciences Inc | 650.39K | 9.88% | 0.0% |
| Orbimed Advisors LLC. | 592.30K | 9.00% | +100.0% |
| Frazier Life Sciences Management, L.P. | 422.50K | 6.42% | 0.0% |
| Stonepine Capital Management, LLC | 225.99K | 3.43% | +252.2% |
| Vanguard Capital Management LLC | 178.52K | 2.71% | +44.4% |
| Sio Capital Management, LLC | 152.46K | 2.32% | 0.0% |
| Adage Capital Partners GP L.L.C. | 111.54K | 1.70% | +100.0% |
| Merck & Co., Inc. | 105.98K | 1.61% | 0.0% |
| Renaissance Technologies, LLC | 64.15K | 0.97% | +29.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of XLO
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 142.44K | 2.16% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 35.61K | 0.54% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 19.46K | 0.30% |
| Bridgeway Funds, Inc.-Ultra-Small Company Fund | 17.54K | 0.27% |
| iShares Trust-iShares Micro-Cap ETF | 8.16K | 0.12% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 5.86K | 0.09% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 5.04K | 0.08% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 4.51K | 0.07% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Vector Equity Portfolio | 1.51K | 0.02% |
| Dimensional ETF Trust-Dimensional US Core Equity 1 ETF | 1.12K | 0.02% |
Frequently asked questions
Who is the largest shareholder of Xilio Therapeutics?
Bain Capital Life Sciences Investors, LLC is the largest institutional shareholder of XLO, owning 10.09% of shares outstanding (664.02K shares) as of its latest 13F filing.
What percentage of Xilio Therapeutics is owned by institutions?
Institutions own about 50.2% of XLO shares and 67.8% of the public float.
How much of Xilio Therapeutics do insiders own?
Insiders, such as officers and directors, own about 25.98% of XLO shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.